Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma

Mrinal Gounder, Albiruni R. Abdul Razak, Adrienne M. Gilligan, Hoyee Leong, Xiwen Ma, Neeta Somaiah, Sant P. Chawla, Javier Martin-Broto, Giovanni Grignani, Scott M. Schuetze, Bruno Vincenzi, Andrew J. Wagner, Bartosz Chmielowski, Robin L. Jones, Jatin Shah, Sharon Shacham, Michael Kauffman, Richard F. Riedel, Steven Attia

Research output: Contribution to journalArticlepeer-review


Objective: Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. Materials and methods: HRQoL was assessed at baseline and day 1 of each cycle using the European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire. Results were reported from baseline to day 169 (where exposure to treatment was maximized while maintaining adequate sample size). Results: Pain scores worsened for placebo versus selinexor across all postbaseline visits, although differences in HRQoL at some visits were not significant. Other domains did not exhibit significant differences between arms; however, scores in both arms deteriorated over time. Conclusion: Patients treated with selinexor reported lower rates and slower worsening of pain compared with patients who received placebo.

Original languageEnglish (US)
Pages (from-to)2923-2939
Number of pages17
JournalFuture Oncology
Issue number22
StatePublished - Aug 2021


  • advanced liposarcoma
  • pain
  • patient-reported outcomes
  • progression-free survival
  • quality of life
  • selective inhibitor of nuclear export
  • selinexor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma'. Together they form a unique fingerprint.

Cite this